SynthesisMolecular psychiatry2025
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Synthesis in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.Molecular psychiatry · 2026Pooled it
- Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic and Mechanistic Review.International journal of molecular sciences · 2026Pooled it
- Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review.Frontiers in psychiatry · 2026Pooled it
- Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use.Community mental health journal · 2026Article
- A contemporary exploration of motivations and practices of psychedelic use among emerging adult cannabis users in the United States: A qualitative analysis.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2026Article
- Candidate Biomarkers of Bipolar Disorder Progression: Implications for Ketamine and Psychedelic Interventions.Molecular neurobiology · 2026Review
- The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.Journal of psychopharmacology (Oxford, England) · 2026Review
- Changes over time in hallucinogen-related emergency department visits in Ontario, Canada.Addiction (Abingdon, England) · 2026Article
- Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026Review
- Unusual experiences and early-onset psychosis associated to hallucinogen use in adolescents: a systematic review and meta-analysis.Child and adolescent psychiatry and mental health · 2026Review
- Perceived Availability of Lysergic Acid Diethylamide in the United States from 2015 to 2019.Psychedelic medicine (New Rochelle, N.Y.) · 2026Article
- Psilocybin and Bipolar Depression: Promise and Prudence.CNS drugs · 2026Review
- Psychedelic therapeutics in psychiatric conditions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Sexsomnia - a detailed approach to evaluation.Frontiers in sleep · 2026Review
- Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service.Frontiers in public health · 2026Article
- Biased Signaling in Psychedelic Action.Annual review of pharmacology and toxicology · 2026Review
- Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.Therapeutic advances in psychopharmacology · 2026Article
- Psychedelics, psychosis, and the elusive notion of safety.Molecular psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders.
methodsWe conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of psychedelic-induced psychosis and symptom exacerbation in schizophrenia. Our pre-registered protocol (CRD42023399591) covered: LSD, psilocybin, mescaline, DMT, and MDMA, using data from Embase, PubMed, PsyARTICLES, PsyINFO, and trial registries up to November 2023. A random-effects model was used to calculate psychosis incidence, with standardized assessments of study quality.
resultsFrom 131 publications, we analyzed 14 systematic reviews, 20 reviews, 35 randomized-controlled trials (RCTs), 10 case-control studies, 30 uncontrolled trials (UCTs), and 22 cohort studies, most of which were low quality. Meta-analysis of nine studies showed an incidence of psychedelic-induced psychosis at 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs. In UCTs including individuals with schizophrenia, 3.8% developed long-lasting psychotic symptoms. Of those with psychedelic-induced psychosis, 13.1% later developed schizophrenia. Sensitivity analyses confirmed the results.
conclusionIn summary, the reviewed evidence suggests that schizophrenia might not be a definite exclusion criterion for clinical trials exploring safety and efficacy of psychedelics for treatment-resistant depression and negative symptoms. However, given the low quality and limited number of studies, more high-quality research is needed, and a conservative approach is recommended until further data is available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.